Los Angeles Superintendent Praised By Gavin Newsom Placed On Leave Following FBI Raid Los Angeles schools were thrown into chaos after the FBI raided the home and office of embattled Superintendent Alberto Carvalho in connection with a widening investigation into a $6 million deal between the nation's second-largest school system and an AI startup . Days later, the district’s board put him on paid...
Los Angeles Superintendent Praised By Gavin Newsom Placed On Leave Following FBI Raid Los Angeles schools were thrown into chaos after the FBI raided the home and office of embattled Superintendent Alberto Carvalho in connection with a widening investigation into a $6 million deal between the nation's second-largest school system and an AI startup . Days later, the district’s board put him on paid administrative leave (he makes $440,000 a year). The F.B.I. raided the home of Alberto M. Carvalho, superintendent of the Los Angeles Unified School District, and the district offices on Wednesday. Credit...Philip Cheung for The New York Times According to federal officials, the agency executed a series of search warrants which included Carvalho's home - during which they seized Carvalho’s work phone and other devices during Wednesday’s raid, according to district insiders. By Friday, the Board of Education voted unanimously to sideline him. Veteran administrator Andres Chait, the district’s chief of school operations, will step in as interim superintendent. At the center of the FBI probe is a collapsed ed-tech startup called AllHere, which was given a $6 million LAUSD contract to build an artificial intelligence chatbot named “Ed,” pitched as a revolutionary tool to “democratize education.” Carvalho personally championed the project after arriving in Los Angeles in 2022 , touting it at tech conferences as a game-changing way for students and parents to stay connected. And of course, the bot was bullshit, and AllHere's founder - Joanna Smith-Griffin, now faces federal fraud charges for allegedly inflating revenues and exaggerating the company’s client base. The criminal case remains unresolved as both sides discuss a possible deal, court records show. Sources familiar with the investigation say the federal probe appears to have expanded beyond AllHere’s collapse to examine Carvalho’s dealings with Debra Kerr , a consultant who helped connect the startup with school distric...
Goldman Sachs Group Inc. Chairman David Solomon said the reaction in financial markets to the Middle East conflict has been “benign” and it will take weeks to understand more about the situation. “It’s very hard to speculate because there is so much that is unknown at this point,” Solomon said at the Australian Financial Review Business Summit in Sydney on Wednesday. Investors are considering whet...
Goldman Sachs Group Inc. Chairman David Solomon said the reaction in financial markets to the Middle East conflict has been “benign” and it will take weeks to understand more about the situation. “It’s very hard to speculate because there is so much that is unknown at this point,” Solomon said at the Australian Financial Review Business Summit in Sydney on Wednesday. Investors are considering whether or not this will become a more prolonged event and if it will start to impact consumption, he added. Read more: Iran War Oil Shock Threatens to Unleash Wave of Global Inflation US assurances on securing shipping through the Strait of Hormuz have helped steady nerves in markets. Still, the Iran war has reverberated across the region, with Israel bombarding Tehran in a fresh wave of strikes. The Islamic Republic fired missiles at Qatar, Bahrain and Oman, with Doha saying targets weren’t limited to military interests. “I look at the market reaction and I’m actually surprised,” Solomon said. “The market reaction has been benign.” Meantime, traders are reducing expectations for interest-rate cuts from the Federal Reserve as the war drives fears of a resurgence in inflation from higher oil prices. Solomon said he wasn’t surprised to see the VIX Index spike and other volatility measures also climb. “It’s going to take a couple of weeks for markets to really digest the implications,” he said. ‘OK, Time to Go’: Cabs, Cash and Twisted Routes to Escape Dubai Howard Marks Says Don’t Let Emotions Cloud Judgment on War Macquarie Evacuates Some Staff Amid Fears Iran War Will Escalate
Mac合家欢 正如期待那样，苹果刚刚通过「官网直接上架」+「新闻稿」的方式，推出了最新的 M5 Pro/Max 款 MacBook Pro 和一大堆 Mac 更新。 这次上新的 MacBook Pro 相比昨天发布的「闹人」iPhone 17e，让人兴奋的元素少了一些。 毕竟它和爱范儿去年测试过的 M5 MacBook Pro 的唯一区别，就是处理器新增了 M5 Pro 和 M5 Max 两种规格...
Mac合家欢 正如期待那样，苹果刚刚通过「官网直接上架」+「新闻稿」的方式，推出了最新的 M5 Pro/Max 款 MacBook Pro 和一大堆 Mac 更新。 这次上新的 MacBook Pro 相比昨天发布的「闹人」iPhone 17e，让人兴奋的元素少了一些。 毕竟它和爱范儿去年测试过的 M5 MacBook Pro 的唯一区别，就是处理器新增了 M5 Pro 和 M5 Max 两种规格， 除此之外再无变化 。 ▲ 图｜Apple 而这次的 M5 Pro 与 M5 Max 处理器，的确有一些可以让人刮目相看的资质。 M5 Pro/Max 相比标准版 M5，差异最大的自然是核心数量。 根据爱范儿去年基于标准版 M5 处理器的评测，哪怕仅仅 10+10 核心的 M5，在很多追求本地算力的应用中已经可以追平当年的「巨无霸」M1 Max 了。 关联阅读： MacBook Pro M5 首发评测：苹果最接近「游戏本」的一次？ 而规模更大的 M5 Pro 与 M5 Max，毫无疑问将会成为 2026 年 Mac 家族中的性能标杆。 目前我们看到，M5 Pro 的起步配置为 15 核 CPU + 16 核 GPU，最高可选配 18 核 CPU + 20 核 GPU 的组合： 而 M5 Max 的核心配置则来到了 18 核 CPU + 32 核 GPU 起步、18 核 CPU + 40 核 GPU 封顶的规模。 鉴于本次 N3P 工艺的进步，双端性能再创新高不是梦： 同时，本次 M5 家族的神经网络加速器规模同样不容小觑。 去年的标准版 M5 上，苹果就为每颗 GPU 核心都内置了「新一代神经网络加速器」，让 Msty Studio 和 VidHex 之类本地 AI 工具取得了不俗的效果： ▲ 在 Msty Studio 中使用相同指令测试首词元响应速度 而相同的神经网络加速器应用到 M5 Pro 与 M5 Max 规模更加庞大的 GPU 核心之后，其在本地机器学习和 AI 加速方面的表现只会更加出色—— 根据苹果的介绍，M5 Pro 在 LLM 提示词中「相比 M1 Pro 可以实现 6.9 倍的提升」，M5 Max 则相比 M1 Max 实现了 6.6 倍的飞跃： 同时我们也能看到，在代码编译场景下，M5 Pro 不仅相比 M1 有接近 2.5 倍的提升，其表现甚至比...
Samsung Electronics announced new breakthroughs with AMD across Samsung’s network portfolio — including 5G Core, virtualized RAN (vRAN) and private networks. This achievement marks a key milestone for both companies that move forward from the joint verification stage to commercial deployments, reinforcing the level of the strategic collaboration for software and AI-driven network innovation. Recen...
Samsung Electronics announced new breakthroughs with AMD across Samsung’s network portfolio — including 5G Core, virtualized RAN (vRAN) and private networks. This achievement marks a key milestone for both companies that move forward from the joint verification stage to commercial deployments, reinforcing the level of the strategic collaboration for software and AI-driven network innovation. Recently, Samsung was selected by Videotron to deploy its 5G Non-Standalone (NSA) and 4G LTE Core gateway solutions, powered by AMD EPYC 9005 Series CPUs. Through this project, Samsung is expanding its presence across Canada and beyond, accelerating its cloud-native AI core footprint while retaining operator confidence in Samsung’s proven partner ecosystem and network solutions. At MWC 2026, Samsung will demonstrate its AI-RAN breakthrough developments by leveraging its AI-powered vRAN with AMD EPYC processors. Following last year’s validation milestone, both companies will introduce the successful results of multi-cell testing conducted at Samsung’s R&D Lab, enabling scalable deployments and greater processor flexibility within software-based network environments. This achievement highlights Samsung’s ability and commitment to reach commercial-grade, AI-powered vRAN performance using a fully virtualized software stack on the latest AMD CPU without additional accelerators. It underscores Samsung’s ongoing shift toward software-driven architectures designed to reduce hardware dependency and provide operators with greater choice and adaptability. The companies have also expanded their joint efforts for AI-driven enterprise solutions. At MWC, Samsung will present its Network in a Server (NIS) — a fully virtualized next-generation, Edge-AI solution powered by AMD’s CPU. This solution helps operators easily incorporate AI into their networks, reduce operational complexity and unlock new opportunities. Samsung will demonstrate various AI on RAN use cases using NIS verified in real-wor...
Equity markets have been fairly volatile so far this year. This can scare off some investors, but it's important to keep in mind that, even with significant short-term seesawing, equities tend to perform well over the long run. And to earn even higher returns than major indexes, it helps to invest in stocks that can navigate the volatile times and post strong financial results throughout and beyon...
Equity markets have been fairly volatile so far this year. This can scare off some investors, but it's important to keep in mind that, even with significant short-term seesawing, equities tend to perform well over the long run. And to earn even higher returns than major indexes, it helps to invest in stocks that can navigate the volatile times and post strong financial results throughout and beyond. Let's consider two growth stocks that have what it takes to pull that off: Eli Lilly (LLY 1.01%) and Veeva Systems (VEEV +2.75%). Here's why both are worth buying now and holding onto for a while. 1. Eli Lilly Eli Lilly is arguably one of the best growth stocks in the pharmaceutical industry right now. Here are three reasons why. First, the company's top-line growth rates in recent quarters have been outstanding. It has performed more like a smaller tech stock than a pharmaceutical giant in this regard. Growth rates in the mid double digits are already very strong for a large drugmaker. Eli Lilly's has been well above that. Second, the company is the leader in the rapidly growing market for anti-obesity medicines. Eli Lilly's tirzepatide, approved for weight loss and obesity, became the world's best-selling drug last year. Expand NYSE : LLY Eli Lilly Today's Change ( -1.01 %) $ -10.24 Current Price $ 1007.73 Key Data Points Market Cap $960B Day's Range $ 995.07 - $ 1020.01 52wk Range $ 623.78 - $ 1133.95 Volume 2.8M Avg Vol 3.2M Gross Margin 83.04 % Dividend Yield 0.61 % The company should launch orforglipron, an oral GLP-1 drug, this year. And in the next couple of years, Eli Lilly should earn approval for at least one other medicine in this area. Third, Eli Lilly has a large pipeline beyond its core diabetes and obesity markets. The company is developing medicines across immunology, oncology, neuroscience, and more. What's more, Eli Lilly has invested heavily in AI-powered initiatives to accelerate the development and marketing of drugs. It also seems to be at the fore...
Key Points Eli Lilly should continue to post top-line growth well above the industry average. Veeva Systems has lots of fuel to achieve its ambitious 2030 goal. 10 stocks we like better than Eli Lilly › Equity markets have been fairly volatile so far this year. This can scare off some investors, but it's important to keep in mind that, even with significant short-term seesawing, equities tend to p...
Key Points Eli Lilly should continue to post top-line growth well above the industry average. Veeva Systems has lots of fuel to achieve its ambitious 2030 goal. 10 stocks we like better than Eli Lilly › Equity markets have been fairly volatile so far this year. This can scare off some investors, but it's important to keep in mind that, even with significant short-term seesawing, equities tend to perform well over the long run. And to earn even higher returns than major indexes, it helps to invest in stocks that can navigate the volatile times and post strong financial results throughout and beyond. Let's consider two growth stocks that have what it takes to pull that off: Eli Lilly (NYSE: LLY) and Veeva Systems (NYSE: VEEV). Here's why both are worth buying now and holding onto for a while. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » 1. Eli Lilly Eli Lilly is arguably one of the best growth stocks in the pharmaceutical industry right now. Here are three reasons why. First, the company's top-line growth rates in recent quarters have been outstanding. It has performed more like a smaller tech stock than a pharmaceutical giant in this regard. Growth rates in the mid double digits are already very strong for a large drugmaker. Eli Lilly's has been well above that. Second, the company is the leader in the rapidly growing market for anti-obesity medicines. Eli Lilly's tirzepatide, approved for weight loss and obesity, became the world's best-selling drug last year. The company should launch orforglipron, an oral GLP-1 drug, this year. And in the next couple of years, Eli Lilly should earn approval for at least one other medicine in this area. Third, Eli Lilly has a large pipeline beyond its core diabetes and obesity markets. The company is developing medicines across immunology, oncology, neuroscien...
It also says only authorised employees can look at direct messages and only in certain situations, such as in response to a valid law enforcement request or a user report about harmful behaviour.
It also says only authorised employees can look at direct messages and only in certain situations, such as in response to a valid law enforcement request or a user report about harmful behaviour.
CrowdStrike delivered robust quarterly results on Tuesday, exceeding expectations across all key measures. Still, the market was wavering on whether AI would be the company's friend or foe. We believe it's the former. Revenue in the fiscal fourth quarter increased 23% year over year to $1.305 billion, beating the consensus estimate of $1.297 billion compiled by market data provider LSEG. Adjusted ...
CrowdStrike delivered robust quarterly results on Tuesday, exceeding expectations across all key measures. Still, the market was wavering on whether AI would be the company's friend or foe. We believe it's the former. Revenue in the fiscal fourth quarter increased 23% year over year to $1.305 billion, beating the consensus estimate of $1.297 billion compiled by market data provider LSEG. Adjusted earnings per share (EPS) increased to $1.12 in the three months ended Jan. 31, beating the $1.10 estimate, according to LSEG. Shares of the cybersecurity provider dipped less than 1% in after-hours trading. CRWD 1Y mountain CrowdStrike 1-year return Bottom line For CrowdStrike to trade higher, the market needed to see a combination of two things. First, a continuation of its strong financial performance, which did not disappoint, with a round of clean beats and upbeat forward guidance for the new fiscal year. Second was a change in the company's narrative. The reason CrowdStrike shares are down 16% this year, alongside many other enterprise software companies, is that some investors believe that large language models (LLMs), with their rapidly improving capabilities, will one day displace even the best traditional cybersecurity vendors. We acknowledge the risks out there, but we are not one of those investors. Instead, we agree with CrowdStrike founder and CEO George Kurtz, who, in the earnings release, said the "AI revolution is increasing a massive growth opportunity" for the company, and that its "technology, team, and ecosystem are well positioned to continue winning." During the earnings call, Kurtz reiterated that AI is "driving elevated demand" for the company's Falcon platform — its cloud-based AI-powered cybersecurity platform — and has become a "key accelerant" for the business. "CrowdStrike is an AI adoption accelerator," Kurtz explained. "Our customers are safely and securely using more than 1,800 distinct AI applications on their endpoints, which would not be p...
Photographer: David Ryder/Bloomberg The congressional committee investigating disgraced financier Jeffrey Epstein is seeking transcribed interviews with Microsoft Corp. co-founder Bill Gates and Apollo Global Management co-founder Leon Black. The two billionaires were among seven people House Oversight Committee Chair James Comer sent letters to on Tuesday requesting interviews for the panel’s inv...
Photographer: David Ryder/Bloomberg The congressional committee investigating disgraced financier Jeffrey Epstein is seeking transcribed interviews with Microsoft Corp. co-founder Bill Gates and Apollo Global Management co-founder Leon Black. The two billionaires were among seven people House Oversight Committee Chair James Comer sent letters to on Tuesday requesting interviews for the panel’s investigation. Most Read from Bloomberg “Due to public reporting, documents released by the Department of Justice, and documents obtained by the Committee, the Committee believes you have information that will assist in its investigation. Accordingly, we request your testimony at an in person transcribed interview,” the panel wrote in letters released to the public. Other recipients include Goldman Sachs Group Inc. General Counsel Kathryn Ruemmler, who said through a spokesperson that she “welcomes” the chance to address questions. The letters included specific dates requesting each of the recipients appear in front of the committee in the coming months. The requested interviews represent the latest effort from House Republicans to shed light on Epstein’s connections to wealthy and powerful figures. Former President Bill Clinton and his wife former Secretary of State Hillary Clinton testified in closed-door depositions last week, videos of which were later made public. Gates has called his relationship with Epstein a “huge mistake” but has denied any wrongdoing. Black became one of Epstein’s main sources of income in the decade after Epstein pleaded guilty in 2008 to a pair of state charges, including procuring a minor to engage in prostitution. Black handed off leadership of Apollo in early 2021. Apollo has said there is no evidence that Epstein or any Epstein entity had any relationship with the company or any of its funds despite the convicted sex offender’s repeated efforts to ingratiate himself with other senior executives. Representatives for Gates Ventures and Black did...
Arne Slot began the week by saying that he found most Premier League games no longer a joy to watch. The Liverpool boss certainly won't have changed his mind after his side's performance in their 2-1 defeat at bottom club Wolves. As Rob Edwards raced down the touchline in Jose Mourinho-esque fashion to celebrate Andre's 94th-minute winner, Liverpool felt very different emotions. The sight of the a...
Arne Slot began the week by saying that he found most Premier League games no longer a joy to watch. The Liverpool boss certainly won't have changed his mind after his side's performance in their 2-1 defeat at bottom club Wolves. As Rob Edwards raced down the touchline in Jose Mourinho-esque fashion to celebrate Andre's 94th-minute winner, Liverpool felt very different emotions. The sight of the away end at Molineux emptying before the final whistle summed it up. Yet again this season, just when it seemed as if Liverpool were making progress, they suffered a brutal defeat. Liverpool have nine league games left and right now, the possibility of missing out on next season's Champions League is a genuine concern. The financial impact of that cannot be underestimated. Slot will know his side simply cannot afford to miss out. On Tuesday, Liverpool failed to create enough and were punished defensively. And again, they conceded an injury-time winner. For Slot, the concerns are only growing, even if he attempted to defend his side by saying that Wolves have hit form. "How do I sum this up? Same old story," said Slot after the game. "My expectations have changed throughout the season because I expected more from us and what we are fighting for now. But it's another setback and we didn't help ourselves with this result, not at all. "That [dropping points] is a concern because it is not the first time we have dropped points against teams that are in these positions. "But we are not the first team to drop points here, last week it was [Aston] Villa, the week before Arsenal. So they are having a good momentum." For a team historically known for scoring late winners, it has been a different story for Liverpool this season. They have lost five Premier League games thanks to injury-time goals - the most ever by any team in a single campaign. "I think it is down to ourselves," said captain Virgil van Dijk after the game. "It was slow, we were predictable, sloppy in possession and wr...
Earnings Call Insights: Cumberland Pharmaceuticals (CPIX) Q4 2025 Management View CEO A.J. Kazimi began the call stating, "2025 was an outstanding year for Cumberland. We announced breakthrough clinical study results, delivered strong financial performance, expanded our global reach and added to our commercial portfolio, highlighting a year of consistent progress for our company." He highlighted a...
Earnings Call Insights: Cumberland Pharmaceuticals (CPIX) Q4 2025 Management View CEO A.J. Kazimi began the call stating, "2025 was an outstanding year for Cumberland. We announced breakthrough clinical study results, delivered strong financial performance, expanded our global reach and added to our commercial portfolio, highlighting a year of consistent progress for our company." He highlighted a 31% increase in fourth quarter revenues to $13.7 million and an 18% full-year revenue growth to $44.5 million, achieving their goal of double-digit revenue growth. Kazimi emphasized the "dramatic growth for Vibativ and Sanucuso, along with the initial sales of our newest brand, Talicia, which we began shipping in the fourth quarter." He also detailed Vibativ's regulatory approval in China and initial launch in Saudi Arabia, as well as ibuprofen injection approval in Mexico. The CEO pointed to the acquisition of Talicia as a strategic addition, stating, "We added Talicia, an FDA-approved treatment for Helicobacter pylori infections, expanding our presence in gastrointestinal care." He further noted the issuance of a J-code for Caldolor by CMS, improving product access and billing for hospitals. Kazimi shared progress in the clinical pipeline, particularly the FIGHT DMD clinical study for ifetroban, which received orphan drug, rare pediatric disease, and Fast Track designations from the FDA. John Hamm, CFO, reported, "For the 3 months ending December 31, 2025, net revenue from continuing operations was $13.7 million, which represented a $3.2 million or a 31% increase over the prior year period." He added, "Net revenues for the full year of 2025 were $44.5 million, a $6.7 million or 18% increase over the prior year." Hamm also described a $3 million milestone payment from Vibativ's approval in China and noted, "Cash flow from operations was $4.9 million in 2025." Outlook Kazimi stated, "As we look ahead, we're once again targeting double-digit revenue growth in 2026, driven b...